| Business Summary | | SuperGen
Inc.
is
a
pharmaceutical
company
dedicated
to
the
acquisition,
rapid
development
and
commercialization
of
oncology
therapies
for
solid
tumors
and
hematological
malignancies.
The
Company's
cancer
products
include
Rubitecan,
Nipent,
Decitabine,
Avicine,
Lucanthone
and
4-HC,
as
well
as
Generic
Anticancer
Drugs.
The
Company
is
also
working
on
the
application
of
its
technologies
to
the
development
of
improved
formulations
of
existing
anticancer
agents,
which
will
be
marketed
as
brand
name
pharmaceuticals.
These
include
Extra
Technology,
Spartaject
Drug
Delivery
Technology,
Oral
Prodrug
Delivery
Technology,
Cremophor-Free
Paclitaxel,
Inhaled
Cancer
Drugs
and
Surface
Safe. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SuperGen
is
a
pharmaceutical
company
dedicated
to
the
acquisition,
rapid
development
and
commercialization
of
oncology
therapies
for
solid
tumors
and
hematological
malignancies.
For
the
six
months
ended
6/30/01,
total
revenues
rose
35%
to
$5.4
million.
Net
loss
increased
73%
to
$26.7
million.
Results
reflect
higher
domestic
and
European
sales
of
Nipent
due
to
additional
marketing
efforts
by
the
sales
staff,
offset
increased
costs
related
to
clinical
trials. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Joseph Rubinfeld, Ph.D., 68 Pres,
CEO, Director | $1.3M | Karl Mettinger, M.D., Ph.D., 57 Sr.
VP, CMO | 126K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|